NYSE · SOLV
Healthcare · Medical - Care Facilities
$90.11
Down-$1.58 (-1.72%)
Updated Sep 9, 2026, 5:03 AM
SID Score
7.3/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
SOLV closed at $90.11 after 20 trading sessions, up 7.15% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 8, 2026 | $90.74 | $91.01 | $89.295 | $90.11 | 1.11M |
| Sep 4, 2026 | $91.40 | $92.275 | $91.375 | $91.69 | 576.35K |
| Sep 3, 2026 | $93.54 | $94.12 | $91.34 | $92.44 | 784.32K |
| Sep 2, 2026 | $91.12 | $93.1099 | $91.12 | $91.90 | 826.11K |
| Sep 1, 2026 | $92.59 | $94.16 | $90.745 | $90.95 | 1.11M |
| Aug 31, 2026 | $90.33 | $91.64 | $90.304 | $91.06 | 926.44K |
| Aug 28, 2026 | $90.98 | $91.70 | $90.69 | $91.12 | 678.87K |
| Aug 27, 2026 | $90.52 | $92.26 | $89.51 | $90.93 | 687.43K |
| Aug 26, 2026 | $91.48 | $92.71 | $91.16 | $91.53 | 1.02M |
| Aug 25, 2026 | $90.79 | $92.05 | $90.35 | $91.61 | 1.05M |
| Aug 24, 2026 | $89.45 | $91.51 | $89.30 | $91.25 | 1.14M |
| Aug 21, 2026 | $88.29 | $89.65 | $87.915 | $89.57 | 925.25K |
| Aug 20, 2026 | $87.09 | $89.44 | $87.03 | $88.61 | 805.06K |
| Aug 19, 2026 | $87.88 | $89.745 | $87.67 | $87.81 | 917.87K |
| Aug 18, 2026 | $87.50 | $88.47 | $87.03 | $87.45 | 1.16M |
| Aug 17, 2026 | $87.75 | $88.125 | $86.64 | $86.82 | 1.52M |
| Aug 14, 2026 | $86.14 | $89.48 | $85.29 | $88.59 | 1.45M |
| Aug 13, 2026 | $85.72 | $86.81 | $85.29 | $86.46 | 1.23M |
| Aug 12, 2026 | $83.23 | $85.595 | $82.25 | $85.29 | 833.98K |
| Aug 11, 2026 | $84.43 | $86.3299 | $84.05 | $84.10 | 773.87K |
The latest Smart Investors Daily articles mentioning SOLV.
SOLV research
Company profile and research snapshot.
In spring 2024, 3M spun out its legacy healthcare segment as a stand-alone firm, Solventum. At that time, the firm comprised four segments. The smallest one—purification and filtration—has since been sold. Now, medsurg is the largest business, contributing roughly 64% of consolidated revenue, and includes advanced wound care and wound prevention. Dental solutions (restorative composites and orthodontia) and health information systems (mainly revenue cycle management) each contribute 18% of total revenue.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | Wedbush | Outperform | — |
| Aug 6, 2026 | Piper Sandler | Overweight | — |
| Aug 6, 2026 | UBS | Buy | — |
| Aug 6, 2026 | Keybanc | Overweight | — |
| Aug 6, 2026 | Stifel | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 2, 2026
Solventum (NYSE: SOLV) announced today that management will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, Sept. 9, 2026, beginning at approximately 10:15 a.m. EDT in Boston, MA.
Yahoo · Sep 2, 2026
Solventum's growth, higher earnings outlook and cost cuts strengthen its case, but heavy debt and 2027 margin risks temper the upside.
Fintel · Aug 28, 2026
Yahoo · Aug 28, 2026
Solventum’s 22% return over the past six months has outpaced the S&P 500 by 10.4%, and its stock price has climbed to $89.05 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SOLV.
